Demographic data of whole group and subgroups of follow up study population
| Whole group(n = 156)(50 females) | Subjects with FEV1 change data | |||||
|---|---|---|---|---|---|---|
| Exposed ⩾1 year(n = 90) | Step-up(n = 114) | Post-removal(n = 86) | Exposed ⩾1 year and step-up(n = 63) | Exposed ⩾1 year and post-removal(n = 44) | ||
| Age at first symptoms (years) | 40.2 | 40.4 | 40.2 | 40.3 | 39.6 | 40 |
| Baseline FEV1 (% predicted) | 89.4 | 88.4 | 88.7 | 87.5 | 89.9 | 86.3 |
| Atopic (%) | 45 | 45.5 | 39 | 37.3 | 39.2 | 30.6 |
| Current/ex/never smokers (%) | 24/28/48 | 20.5/30.7/48.9 | 21.6/28.8/49.5 | 22.9/30.1/47 | 18/31.1/50.8 | 21.4/33.3/45.2 |
| On inhaled steroids at time of removal from exposure | 82.7 | 80 | 77.2 | 80.2 | 81 | 86.4 |
| Increased bronchial hyperresponsiveness at diagnosis (%) | 63.6 | 62.8 | 61.5 | 65.2 | 51.1 | 67.6 |
| Median latent interval between first exposure and symptoms (months) | 64 | 72 | 64 | 72 | 72 | 66 |
| Duration of symptomatic exposure (months) | 45 | 57 | 42 | 41 | 57 | 55 |